Bioidentical hormones vs standard HRT: what is the difference?

Short answer

• “Bioidentical” hormones are molecules that have the same chemical structure as human hormones (typically estradiol, progesterone, testosterone). “Standard” HRT often refers to older/synthetic products (conjugated equine estrogens or synthetic progestins) but the term is used loosely. The important differences are in chemical structure, regulation, and the evidence base — not in a clear-cut safety advantage for one label vs the other.

Definitions and key points

• Bioidentical hormones: chemically identical to human hormones (example: 17β‑estradiol, micronized progesterone). They can be prescribed as FDA‑approved products (made by pharma companies) or made by compounding pharmacies (custom doses/mixtures).
• Standard/synthetic HRT: includes non‑bioidentical estrogens/progestins such as conjugated equine estrogens (Premarin) or synthetic progestins (medroxyprogesterone acetate — Provera). These have been widely studied (including in large trials such as the Women’s Health Initiative).
• Compounded bioidentical hormone therapy (CBHT): custom mixes made by compounding pharmacies. These are not FDA‑approved, have variable quality/dosing, and lack the same safety/efficacy testing as approved drugs.

What the evidence says (brief)

• There is no convincing evidence that compounded bioidentical hormones are safer or more effective than FDA‑approved HRT.
• Risks depend on the hormone type, dose, route (oral vs transdermal), duration, and whether you still have a uterus (unopposed systemic estrogen raises endometrial cancer risk unless progesterone or a progestin is added).
• Some data suggest transdermal estradiol (patch/gel) may have a lower risk of blood clots than oral estrogen. Micronized progesterone (Prometrium) may have a different risk profile than synthetic progestins, but evidence is complex.
• Major organizations (FDA, North American Menopause Society, Endocrine Society) recommend using FDA‑approved products when possible and caution about compounded preparations.

Practical differences that matter to patients

• Regulation and quality: FDA‑approved products have consistent dosing and required safety/efficacy data. Compounded products do not.
• Dosing flexibility: compounding pharmacies can create unusual doses/forms (pellets, topical mixes) that pharma products do not offer — sometimes a reason patients choose them.
• Monitoring/testing: saliva hormone tests used to titrate CBHT are not reliable; blood tests are limited in their usefulness for many menopausal HRT decisions.
• Route matters: local low‑dose vaginal estrogen (Vagifem, Estring, estradiol cream) often relieves vaginal dryness/urgency with minimal systemic exposure.

Examples of commonly used, FDA‑approved products (so you and your clinician can discuss specifics)

• Estradiol (bioidentical in structure): Vivelle‑Dot, Climara (patches) — transdermal routes; Estrace (oral estradiol) — systemic; Estring, Vagifem, and estradiol cream (local vaginal therapy) — for vaginal symptoms.
• Micronized progesterone (bioidentical): Prometrium — FDA‑approved oral progesterone for endometrial protection when systemic estrogen is used and for some other indications.
• Conjugated equine estrogens (non‑bioidentical): Premarin — historically common, large trials include Premarin-containing regimens.
• Synthetic progestins (non‑bioidentical): Provera (medroxyprogesterone acetate) — commonly paired with estrogen in combined HRT.
• Pellets/compounded BHRT companies: many clinics/compounding pharmacies offer pellet therapy (e.g., BioTE is a recognizable name in the pellet industry). Note: pellets are generally compounded, have limited trial data versus standard options, and carry risks (insertion complications, inconsistent dosing).

How to choose

• Consider your symptoms (vasomotor vs vaginal), medical history (breast cancer risk, clotting history, cardiovascular disease), whether you have a uterus, and personal preferences for route of administration.
• Prefer FDA‑approved products when possible because of consistent dosing and known safety profiles.
• If a compounding option is desired (e.g., pellet therapy or a custom transdermal mix), discuss the tradeoffs with your clinician and use a reputable, accredited compounding pharmacy. Ask about sterility, quality testing, and batch records.

Next steps

• Discuss options with a clinician experienced in menopause care (primary care, gynecologist, or a menopause specialist). You can mention that you’re interested in bioidentical options and ask specifically:
  • Which HRT formulations are FDA‑approved and appropriate for me?
  • Do I need progesterone with estrogen?
  • What route (oral, patch, gel, vaginal) has the best risk/benefit for my situation?
  • If considering compounded/bioidentical pellets or creams, what evidence supports them and what are the quality controls?

If you want, tell me your main symptoms, medical history (especially clotting, breast cancer, liver disease), and whether you still have a uterus — I can outline likely options and pros/cons tailored to your situation.